0001144204-12-066990.txt : 20121207 0001144204-12-066990.hdr.sgml : 20121207 20121207163150 ACCESSION NUMBER: 0001144204-12-066990 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20121109 FILED AS OF DATE: 20121207 DATE AS OF CHANGE: 20121207 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: TG THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001001316 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 363898269 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 BUSINESS PHONE: (212) 554-4484 MAIL ADDRESS: STREET 1: 787 SEVENTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 FORMER COMPANY: FORMER CONFORMED NAME: MANHATTAN PHARMACEUTICALS INC DATE OF NAME CHANGE: 20030310 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC TECHNOLOGY VENTURES INC DATE OF NAME CHANGE: 20000330 FORMER COMPANY: FORMER CONFORMED NAME: ATLANTIC PHARMACEUTICALS INC DATE OF NAME CHANGE: 19960703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LFB Biotechnologies S.A.S.U. CENTRAL INDEX KEY: 0001377942 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-32639 FILM NUMBER: 121250298 BUSINESS ADDRESS: STREET 1: 3 AVENUE DES TROPIQUES STREET 2: LES ULIS CITY: COURTABOEUF STATE: I0 ZIP: 91958 BUSINESS PHONE: 33 6 33554531 MAIL ADDRESS: STREET 1: 3 AVENUE DES TROPIQUES STREET 2: LES ULIS CITY: COURTABOEUF STATE: I0 ZIP: 91958 3 1 v329815_3.xml OWNERSHIP DOCUMENT X0206 3 2012-11-09 0 0001001316 TG THERAPEUTICS, INC. TGTX 0001377942 LFB Biotechnologies S.A.S.U. 3, AVENUE DES TROPIQUES BP 40305 LES ULIS COURTABOEUF CEDEX I0 91942 FRANCE 0 0 1 0 Common Stock 5000000 D Warrants to purchase Common Stock 0.001 2022-11-09 Common Stock 2500000 D The warrant becomes exercisable following an equity financing or series of equity financings in which TG Therapeutics, Inc. (the "Company") receives gross proceeds of at least $7,500,000. In addition, the warrant may not be exercised if following the exercise LFB Biotechnologies S.A.S. would beneficially own in excess of 19.9% of the Company's outstanding common stock. /s/ Brian Keane, Attorney-in-fact 2012-12-07